Press releases
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
- IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
- /C O R R E C T I O N -- IDEAYA Biosciences, Inc./
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
- IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
- IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
- IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
- IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
More ▼
Key statistics
On Friday, IDEAYA Biosciences Inc (30J:FRA) closed at 32.80, -26.13% below its 52-week high of 44.40, set on Feb 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.80 |
---|---|
High | 32.80 |
Low | 32.80 |
Bid | 33.60 |
Offer | 33.80 |
Previous close | 32.80 |
Average volume | 78.20 |
---|---|
Shares outstanding | 75.69m |
Free float | 74.84m |
P/E (TTM) | -- |
Market cap | 2.77bn USD |
EPS (TTM) | -2.00 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:07 BST.
More ▼